Moderna reports fourth quarter and fiscal year 2021 financial results and provides business updates

Moderna, Inc. ( MRNA), a biotechnology company pioneering messenger RNA (mRNA)therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter of fiscal year 2021.

“Spikevax isnow approved in more than 70 countries around the world protecting hundreds of millions of people and real-world evidence from multiple independent studies has confirmed its strong effectiveness,” said Stéphane Bancel, Chief ExecutiveOfficer of Moderna. “In 2021, we delivered 807 million doses with approximately 25% of those doses going to low- and middle-income countries, and we will continue to scale in 2022 to help end the COVID-19 pandemic.

Moderna has experienced exponential growth and we have more than doubled the size of our team over the last year with a global team of 3,000. We also have announced plans to scale to 21 commercialsubsidiaries across the world, including four new locations in Asia and six new locations in Europe.

We continue to expand and advance our industry-leading mRNA pipeline with 44 programs in development. We look forward to clinical readouts from ourtherapeutics development candidates later in 2022 in rare genetic diseases and oncology. We are entering 2022 with a remarkable team and strategic priorities to continue advancing mRNA vaccines and therapeutics to impact human health.”